Clinical Trials | December 18, 2025
Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
The combination also outperformed chemotherapy on another important secondary endpoint
The combination also outperformed chemotherapy on another important secondary endpoint
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Cresemba is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Subscribe To Our Newsletter & Stay Updated
